

BACIL PHARMA LIMITED

Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099
Email Id: bacilpharma07@gmail.com, CIN: L24200MH1987PLC043427,
Tel: 22618452/22661541, Tel/Fax: 22618327

Date: October 14, 2026

To,
The Manager,
Listing Department,
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001
Scrip Code: 524516

Sub: Outcome of the Board Meeting held on Wednesday, October 14, 2026
Ref: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we wish to inform you that the Meeting of the Board of Directors of Bacil Pharma Limited was held on Wednesday, October 14, 2026 at the Registered Office of the Company, wherein the Board has, inter alia, considered and approved the following:

1. Approved the Unaudited Financial Results of the Company for the half year and quarter ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors of the Company.

The meeting of the Board of Directors commenced at 03:00P.M. and concluded at 04:00 P.M.

The Unaudited Financial Results and Limited Review Report will be submitted separately in the prescribed format as per SEBI LODR Regulations.

Kindly take the above on your record and acknowledge the receipt.

Thanking you,

For Bacil Pharma Limited

Shah Chaitali
Kalpataru

Digitally signed by Shah Chaitali
Kalpataru
Date: 2026.10.14 16:08:52 +05'30'

Chaitali Kalpataru Shah
Director & CFO
Din: 11167778

BACIL PHARMA LIMITED

{CIN : L24200MH1987PLC043427}

Unaudited Financial Results on Standalone basis for the Quarter and Half Year Ended 30th September, 2026

Prepared In Compliance with the Indian Accounting Standards (IND AS)

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended		Half Year Ended		Year ended
		30-09-2026	30-06-2026	30-09-2026	30-09-2025	31-03-2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited
1	Revenue from operations					
	Other income	9.18	8.91	18.09	105.74	123.52
	Total revenue	9.18	8.91	18.09	105.74	123.52
2	Expenses					
	Cost of material consumed	-	-	-	-	-
	Purchases of Stock in trade	-	-	-	-	-
	Employee benefits expense	0.72	0.72	1.44	3.58	4.89
	Finance Cost	-	-	-	-	-
	Depreciation and amortization expense	-	-	-	-	-
	Other expenses	5.21	1.55	6.76	10.96	19.61
	Total expenses	5.93	2.27	8.20	14.54	24.50
	Profit / (Loss) from ordinary activities before tax	3.25	6.64	9.89	91.20	99.02
3	Tax expense:					
	Current tax	0	0	0	0	-
	Deferred tax	4.23	8.25	12.48	22.95	56.53
4	Profit/(Loss) from ordinary activities after tax	(0.98)	(1.61)	(2.59)	68.25	155.55
5	Other Comprehensive Income (OCI)					
	<u>Item that will not be reclassified to profit or loss</u>					
	Gain/(Loss) on recognised on fair valuation of Financial Assets	16.27	31.73	48.01	6.69	(217.43)
	Income tax relating to these items	0	0	-	-0.82	-
	Total Other Comprehensive Income (OCI)	16.27	31.73	48.01	5.87	(217.43)
	Profit/(Loss) for the Period	15.29	30.12	45.42	74.12	(61.88)
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,397.03	1,397.03	1,397.03	1,397.03	1,397.03
6	Earning Per Share (EPS) (Not annualised)					
	(1) Basic	0.11	0.22	0.33	0.53	1.11
	(2) Diluted	0.11	0.22	0.33	0.53	1.11

See notes accompanying to the Financial statements

Notes:

1	The aforesaid unaudited financial results have been reviewed and recommended by Audit Committee and approved by the Board of Directors at their meeting held on 14-10-2026
2	The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per regulations 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
3	The figures for the Quarter / half Year ended 30th September, 2026 are in compliance with the Indian Accounting Standards (Ind AS) notified by the Ministry of Corporate Affairs.
4	The Financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 – Interim Financial reporting, notified under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, and other accounting principles generally accepted in India.
5	The format for above results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated Nov 30, 2015 has been modified to comply with the requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III [Division II] to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6	The Company has only one reportable primary pharmaceutical business segment as per IND AS 108.
7	Figures for the previous period have been regrouped, reclassified and restated wherever necessary to make them comparable with the current period's figures.

As per our report of even date attached.

For Bacil Pharma Limited

Shah
Chaitali
Kalpataru

Digitally signed
by Shah Chaitali
Kalpataru
Date: 2026.10.14
16:06:58 +05'30'

Ms Chaitali Kalpataru Shah

Director & CFO

DIN: 11167778

Place : Mumbai

Date : 14-10-2026

BACIL PHARMA LIMITED			
CIN :L24200MH1987PLC043427			
Regd. Off.: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099			
Email: bacilpha@yahoo.com			
Standalone Balance Sheet as at 30th September,2026			
(Rupees in Lacs)			
Particulars	Note No.	As at 30th September,2026	As at 31st March,2026
I. ASSETS			
1 Non-current assets			
Property Plant and Equipment	3	0.00	0.00
Assets Classified as held for sale			
Property Plant and Equipments		0.00	0.00
Financial Assets			
(a) Investments	4	2235	2424
(b) Loans	5	104.77	78.10
Deferred tax assets (net)	6	49.41	61.89
2 Current assets			
Financial Assets			
(a) Investments			-
(b) Trade receivables		110.89	118.00
(c) Cash and cash equivalents	7	30.31	56.85
Other current assets	8	3.80	0.45
Total		2534.21	2739.26
II. EQUITY AND LIABILITIES			
1 Equity			
Equity Share capital	9	1397.02	1397.02
Other Equity	10	1130.19	1084.24
2 Non-current liabilities			
Financial Liabilities			
Deferred tax liabilities			
3 Current liabilities			
Financial Liabilities			
(a) Borrowings	11	0.00	0.00
(b) Trade Payables	12		
Total outstanding due of			
(A) Micro enterprises and small enterprises			
(B) Creditors other than micro enterprises and small enterprises		6.99	1.97
(c) Other Financial Liabilities		0.00	18.00

Other current liabilities	13	0.00	0.00
Provisions	14	0.00	238.06
Total		2534.21	2739.26

Summary of Significant Accounting Policies

See Other notes to Accounts

**For and on behalf of the Board
BACIL PHARMA LIMITED**

Shah
Chaitali
Kalpataru

Digitally signed
by Shah Chaitali
Kalpataru
Date: 2026.10.14
16:07:24 +05'30'

Ms Chaitali Kalpataru Shah
Director & CFO
DIN : 11167778

Place : Mumbai
Date: 14/10/2026

BACIL PHARMA LIMITED
STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 30th Sep, 2026

(Amount in LAKH)

Particulars	Year ended 30.09.2026	Year ended 31.03.2026
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (Loss) /profit before tax	9.89	99.02
<u>Adjustments for</u>		
Depreciation	0	0
Loss on sale of Fixed Asset	0	0
Increase in DTA	0	-56.53
Interest & Dividend Income	0	0
Operating profit before working capital changes	9.89	42.49
Working Capital adjustments :-		
Increase/(Decrease) in Trade and Other Payables	5.03	1.55
Increase/(Decrease) in Borrowings	0.00	-11.22
Increase/(Decrease) in Provisions	-238.06	238.06
Increase/(Decrease) in Other Financial Liabilities	-18.00	14.1
Increase/(Decrease) in Other Current Liabilities	0.00	-0.09
(Increase)/Decrease in Trade Receivable	7.11	-118.00
(Increase)/Decrease in Deferred tax assets	12.48	0.00
(Increase)/Decrease in Other Current Assets	-3.35	4.57
Cash generated from /(used in) operations	-224.89	171.46
Direct taxes paid (Net of Refunds)		
Net cash (used in)/ from generated from operating activities	-224.89	171.46
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant & Equipment	0	0
Proceeds Purchase/Sale of Investments	0	0
Interest & Dividend Income	0	0
(Increase)/Decrease in Investment	189	-288.31
(Increase)/Decrease in loans	-26.67	-50.15
Net cash (used in)/ from generated from investing activities	162.28	-338.47
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) of Unsecured Loan	0	0
Proceeds from Preferential Allotment of Shares	0	0
Increase/(Decrease) of other equity	36.08	-61.88
Net cash (used in)/ from generated from financing activities	36.08	-61.88

D. Net Increase/Decrease in cash and cash equivalents (A+B+C)	-26.53	-228.88
Cash and Cash equivalents at the beginning of the year	56.85	285.73
Cash and Cash equivalents at the end of the year	30.31	56.85
Notes referred to above form part of Balance Sheet For and on behalf of the Board Bacil Pharma Limited Shah Chaitali Kalpataru Digitally signed by Shah Chaitali Kalpataru Date: 2026.10.14 16:07:37 +05'30' Ms Chaitali Kalpataru Shah Director & CFO DIN : 11167778 Place : Mumbai Date: 14/10/2026		



**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

**LIMITED REVIEW REPORT ON UNAUDITED STANDALONE QUARTERLY
AND HALF YEARLY FINANCIALS RESULTS OF BACIL PHARMA LIMITED
PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS
AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.**

**To the Board of Directors of
BACIL PHARMA LIMITED**

We have accompanying statement of unaudited financial results of **BACIL PHARMA LIMITED** (the "Company") for the Quarter and half year ended 30th September, 2026 (the "Statement") on Standalone basis attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").

- 1) We have reviewed the accompanying statement of unaudited financial results of **BACIL PHARMA LIMITED** (the "Company") for the Quarter ended and half year ended September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").
- 2) Company's Board of Directors responsibility of the Company's Management and Approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.





**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of the Interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit.
- 4) The information and data contained in this report are based solely on the documents, explanations, and representations provided by the management of the entity. We have not independently verified the correctness or completeness of such information and records, and our verification has been limited to the extent of information made available to us during the course of our review.

Other Matters

We have carried out the limited review of the financial results of the Company for the quarter ended and half year ended September 30, 2026 . There is no other qualification in these regards on these financial results.

FOR
SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
CHARTERED ACCOUNTANTS
FRN: 159649W


CA SARANG CHAVAN
(PROPRIETOR)
M.NO.142576
UDIN: 26142576XPIAMZ5913
Date: 14/10/2026
Place: Ahmedabad



BACIL PHARMA LIMITED

(CIN : L24200MH1987PLC043427)

Unaudited Financial Results on Consolidated basis for the Quarter and Half Yearly Ended 30th September, 2026

Prepared In Compliance with the Indian Accounting Standards (IND AS)

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended		Half Year Ended		Year ended
		30-09-2026	30-06-2026	30-09-2026	30-09-2025	31-03-2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited
1	Revenue from operations					
	Other income	9.18	8.91	18.09	105.74	123.52
	Total revenue	9.18	8.91	18.09	105.74	123.52
2	Expenses					
	Cost of material consumed	-	-	-	-	-
	Purchases of Stock in trade	-	-	-	-	-
	Employee benefits expense	0.72	0.72	1.44	3.58	4.89
	Finance Cost	6.24	-	6.24	-	-
	Depreciation and amortization expense	-	-	-	-	-
	Other expenses	5.21	1.55	6.76	10.96	19.61
	Total expenses	12.17	2.27	14.44	14.54	24.50
	Profit / (Loss) from ordinary activities before tax	(2.99)	6.64	3.65	91.20	99.02
3	Tax expense:					
	Current tax	-	-	-	-	-
	Deferred tax	4.23	8.25	12.48	22.95	56.53
4	Profit/(Loss) from ordinary activities after tax	(7.22)	(1.61)	(8.83)	68.25	155.55
5	Other Comprehensive Income (OCI)					
	<u>Item that will not be reclassified to profit or loss</u>					
	Gain/(Loss) on recognised on fair valuation of Financial Assets	16.27	31.73	48.01	6.69	(217.43)
	Income tax relating to these items	-	-	-	-0.82	-
	Total Other Comprehensive Income (OCI)	16.27	31.73	48.01	5.87	(217.43)
	Profit/(Loss) for the Period	9.06	30.12	39.18	74.12	(61.88)
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,397.03	1,397.03	1,397.03	1,397.03	1,397.03
6	Earning Per Share (EPS) (Not annualised)					
	(1) Basic	0.06	0.22	0.28	0.53	1.11
	(2) Diluted	0.06	0.22	0.28	0.53	1.11

See notes accompanying to the Financial statements

Notes:

1	The aforesaid unaudited financial results have been reviewed and recommended by Audit Committee and approved by the Board of Directors at their meeting held on 14-10-2026
2	The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per regulations 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
3	The figures for the Quarter / half Year ended 30th September, 2026 are in compliance with the Indian Accounting Standards(Ind AS) notified by the Ministry of Corporate Affairs.
4	The Financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 – Interim Financial reporting, notified under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, and other accounting principles generally accepted in India.
5	The format for above results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated Nov 30, 2015 has been modified to comply with the requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III [Division II] to the Companies Act, 2013 applicable to companies that are required to comply with Ind As.
6	The Company has only one reportable primary pharmaceutical business segment as per IND AS 108 .
7	Figures for the previous period have been regrouped, reclassified and restated wherever necessary to make them comparable with the current period's figures.

As per our report of even date attached.

For Bacil Pharma Limited

Shah Chaitali
Kalpataru

Digitally signed by
Shah Chaitali Kalpataru
Date: 2026.10.14
16:08:09 +05'30'

Ms Chaitali Kalpataru Shah

Director & CFO

DIN: 11167778

Place : Mumbai

Date : 14-10-2026

BACIL PHARMA LIMITED			
CIN :L24200MH1987PLC043427			
Regd. Off.: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099			
Email: bacilpha@yahoo.com			
Consolidated Balance Sheet as at 30th September,2026			
(Rupees in Lacs)			
Particulars	Note No.	As at 30th September,2026	As at 31st March,2026
I. ASSETS			
1 Non-current assets			
Property Plant and Equipment	3	0.00	0.00
Assets Classified as held for sale			
Property Plant and Equipments		0.00	0.00
Financial Assets			
(a) Investments	4	2235	2424
(b) Loans	5	104.77	78.10
Deferred tax assets (net)	6	49.41	61.89
2 Current assets			
Financial Assets			
(a) Investments			-
(b) Trade receivables		110.89	118.00
(c) Cash and cash equivalents	7	97.41	56.85
Other current assets	8	483.80	0.45
Total		3081.30	2739.26
II. EQUITY AND LIABILITIES			
1 Equity			
Equity Share capital	9	1398.12	1397.02
Other Equity	10	1123.95	1084.24
2 Non-current liabilities			
Financial Liabilities			
Deferred tax liabilities			
3 Current liabilities			
Financial Liabilities			
(a) Borrowings	11	552.24	0.00
(b) Trade Payables	12		
Total outstanding due of			
(A) Micro enterprises and small enterprises			
(B) Creditors other than micro enterprises and small enterprises		6.99	1.97

(c) Other Financial Liabilities		0.00	18.00
Other current liabilities	13	0.00	0.00
Provisions	14	0.00	238.06
Total		3081.30	2739.26

Summary of Significant Accounting Policies

See Other notes to Accounts

Notes referred to above form part of Balance Sheet

For and on behalf of the Board
BACIL PHARMA LIMITED

Shah
Chaitali
Kalpataru

Digitally signed by
Shah Chaitali
Kalpataru
Date: 2026.10.14
16:08:22 +05'30'

Ms Chaitali Kalpataru Shah

Director & CFO

DIN : 11167778

Place : Mumbai

Date: 14/10/2026

BACIL PHARMA LIMITED
CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 30th Sep, 2026

(Amount in LAKH)

Particulars	Year ended 30.09.2026	Year ended 31.03.2026
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (Loss) /profit before tax	3.65	99.02
<u>Adjustments for</u>		
Depreciation	0	0
Loss on sale of Fixed Asset	0	0
Increase in DTA	0	-56.53
Interest & Dividend Income	0	0
Operating profit before working capital changes	3.65	42.49
Working Capital adjustments :-		
Increase/(Decrease) in Trade and Other Payables	5.03	1.55
Increase/(Decrease) in Borrowings	552.24	-11.22
Increase/(Decrease) in Provisions	-238.06	238.06
Increase/(Decrease) in Other Financial Liabilities	-18.00	14.1
Increase/(Decrease) in Other Current Liabilities	0.00	-0.09
(Increase)/Decrease in Trade Receivable	7.11	-118.00
(Increase)/Decrease in Deferred tax assets	12.48	0.00
(Increase)/Decrease in Other Current Assets	-483.35	4.57
Cash generated from /(used in) operations	-158.90	171.46
Direct taxes paid (Net of Refunds)		
Net cash (used in)/ from generated from operating activities	-158.90	171.46
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant & Equipment	0	0
Proceeds Purchase/Sale of Investments	0	0
Interest & Dividend Income	0	0
(Increase)/Decrease in Investment	189	-288.31
(Increase)/Decrease in loans	-26.67	-50.15
Net cash (used in)/ from generated from investing activities	162.28	-338.47
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) of Unsecured Loan	0	0
Proceeds from Preferential Allotment of Shares	0	0
Increase/(Decrease) of other equity	37.18	-61.88
Net cash (used in)/ from generated from financing activities	37.18	-61.88

D. Net Increase/Decrease in cash and cash equivalents (A+B+C)	40.56	-228.88
Cash and Cash equivalents at the beginning of the year	56.85	285.73
Cash and Cash equivalents at the end of the year	97.41	56.85
Notes referred to above form part of Balance Sheet For and on behalf of the Board Bacil Pharma Limited Shah Chaitali Kalpataru Digitally signed by Shah Chaitali Kalpataru Date: 2026.10.14 16:08:36 +05'30' Ms Chaitali Kalpataru Shah Director & CFO DIN : 11167778 Place : Mumbai Date: 14/10/2026		



**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

**LIMITED REVIEW REPORT ON UNAUDITED CONSOLIDATED QUARTERLY
AND HALF YEARLY FINANCIALS RESULTS OF BACIL PHARMA LIMITED
PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS
AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.**

**To the Board of Directors of
BACIL PHARMA LIMITED**

We have accompanying statement of unaudited financial results of **BACIL PHARMA LIMITED** (the "Company") for the Quarter and half year ended **30th September, 2026** (the "Statement") on **Consolidated basis** attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").

- 1) We have reviewed the accompanying statement of unaudited financial results of **BACIL PHARMA LIMITED** (the "Company") for the Quarter ended and half year ended September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").
- 2) Company's Board of Directors responsibility of the Company's Management and Approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.





**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS


CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of the Interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit.
- 4) The information and data contained in this report are based solely on the documents, explanations, and representations provided by the management of the entity. We have not independently verified the correctness or completeness of such information and records, and our verification has been limited to the extent of information made available to us during the course of our review.

Other Matters

We have carried out the limited review of the financial results of the Company for the quarter ended and half year ended September 30, 2026. There is no other qualification in these regards on these financial results.

FOR
SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
CHARTERED ACCOUNTANTS
FRN: 159649W


CA SARANG CHAVAN
(PROPRIETOR)
M.NO.142576
UDIN: 26142576JCTBK1918
Date: 14/10/2026
Place: Ahmedabad

